Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Ewing 2Sarcoma 2Osteosarcoma 2Vascular Neoplasms 1Solitary Fibrous Tumors 1Smooth Muscle Tumor 1Sarcoma, Clear Cell 1Rhabdomyosarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Adipose Tissue 1Myoepithelioma 1Malignant mesenchymal tumor 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Liposarcoma, Myxoid 1Liposarcoma 1Hodgkin Disease 1Histiocytoma, Angiomatoid Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1Granuloma, Plasma Cell 1Granular Cell Tumor 1Glomus Tumor 1Fibrosarcoma 1Disorders of Sex Development 1Dermatofibrosarcoma 1Chondrosarcoma, Extraskeletal Myxoid 1

Interventions

X-Rays 4Phantoms, Imaging 4Nuclear Medicine Department, Hospital 4Magnetic Resonance Spectroscopy 4Vincristine 3Specimen Handling 3Irinotecan 3Cyclophosphamide 3Biopsy 3ulixertinib 2tipifarnib 2selpercatinib 2larotrectinib 2ivosidenib 2ensartinib 2Temozolomide 2Radiotherapy 2temsirolimus 1tazemetostat 1talazoparib 1palbociclib 1olaparib 1liposomal doxorubicin 1irinotecan sucrosofate 1fludarabine phosphate 1fludarabine 1erdafitinib 1cabozantinib 1atezolizumab 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × Ifosfamide × 30 days × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡